Results 141 to 150 of about 168,641 (363)

Biomarkers of lung congestion and injury in acute heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi   +9 more
wiley   +1 more source

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

open access: yes, 2014
Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala   +11 more
core   +2 more sources

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio   +10 more
wiley   +1 more source

Natriuretic peptide system and cardiovascular disease

open access: yesHeart Views, 2010
The mammalian Natriuretic Peptide (NP) system consists of neuro-hormones, such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), c-type natriuretic peptide (CNP), and the N-Terminal fragment of BNP (NT-pro-BNP).
Federico Cacciapuoti
doaj  

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya   +9 more
wiley   +1 more source

Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trialResearch in context

open access: yesEClinicalMedicine, 2023
Summary: Background: TransCon CNP (navepegritide) is an investigational prodrug of C-type natriuretic peptide (CNP) designed to allow for continuous CNP exposure with once-weekly dosing.
Ravi Savarirayan   +22 more
doaj  

Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts.

open access: yesEndocrinology, 2003
C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is known to be synthesized in the central nervous system and vascular endothelial cells, in contrast to atrial natriuretic peptide and brain natriuretic peptide ...
T. Horio   +8 more
semanticscholar   +1 more source

Effects of Intravenously Administered C-type Natriuretic Peptide in Humans: Comparison with Atrial Natriuretic Peptide.

open access: yesHypertension Research, 1998
We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human atrial natriuretic peptide (hANP), we ...
Yasato Komatsu   +9 more
openaire   +4 more sources

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou   +7 more
wiley   +1 more source

N-Terminal pro C-Type Natriuretic Peptide (NTproCNP) and myocardial function in ageing.

open access: yesPLoS ONE, 2018
Ageing-related alterations in cardiovascular structure and function are commonly associated with chronic inflammation. A potential blood-based biomarker indicative of a chronic inflammatory state is N-Terminal Pro C-Type Natriuretic Peptide (NTproCNP ...
Bryan M H Keng   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy